

Advaxis, Inc.  
Form 8-K  
July 07, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 2, 2014**

**ADVAXIS, INC.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: Advaxis, Inc. - Form 8-K

**Delaware**                      **00028489**      **02-0563870**  
(State or other jurisdiction (Commission (IRS Employer  
of incorporation)      File Number) Identification No.)

**305 College Road East**

**08540**

**Princeton, New Jersey**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(609) 452-9813**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On July 2, 2014, Advaxis, Inc. (the “Company”) issued a press release to announce that a request for a product license from the United States Department of Agriculture (“USDA”) has been filed for ADXS-cHER2 by Aratana Therapeutics, Inc. (“Aratana”). The Company previously granted Aratana an exclusive worldwide license to develop and commercialize ADXS-cHER2 for pet therapeutics. While the USDA has no specific obligation to respond within a prescribed timeframe, the Company expects that a response from the USDA to the filing will occur over the next 12 to 18 months. If approval is granted by the USDA, the Company will be entitled to a cash royalty payment by Atarana with respect to the sale of ADXS-cHER2.

A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
--------------------	--------------------

99.1	Press Release of Advaxis, Inc. dated July 2, 2014.
------	----------------------------------------------------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVAXIS, INC.**

By */s/ Daniel J. O'Connor*  
Name: Daniel J. O'Connor  
Title: Chief Executive Officer

Date: July 7, 2014

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1	Press Release of Advaxis, Inc. dated July 2, 2014.
------	----------------------------------------------------

